TY  - JOUR
AU  - Batalli-Kepuska, Arbnora
AU  - Spahiu, Lidvana
AU  - Behluli, Emir
AU  - Temaj, Gazmend
PY  - 2024
DA  - 2024/07/19
TI  - Blinatumomab vs Chemotherapy for Pediatric and Adult Acute Lymphoblastic Leukemia
JO  - OBM Genetics
SP  - 253
VL  - 08
IS  - 03
AB  - Several therapeutic methods are used to cure acute lymphoblastic leukemia (ALL). Relapsed/refractory B-cell ALL (R/R B-ALL) remains the primary cause of death worldwide due to the limitation of cure. Blinatumomab is a bispecific T-cell engaging antibody used to treat R/R B-ALL. The use of blinatumomab for treating R/R B-ALL has shown to be very efficient, especially as a bridge tool to hematopoietic stem cell transplantation (HSCT). The response to blinatumomab treatment ranged from 69% after two cycles in phase II clinical trials. Blinatumomab has shown great anti-leukemia activity as a single agent in children with R/R B-ALL. Here, we will review the data from several research groups that show pharmacological and clinical data on blinatumomab for pediatric and adult B-ALL, both as an immunotherapeutic and in combination.
SN  - 2577-5790
UR  - https://doi.org/10.21926/obm.genet.2403253
DO  - 10.21926/obm.genet.2403253
ID  - Batalli-Kepuska2024
ER  -